← All companies
PALX
Palomino Laboratories Inc.
$13.15
+0.30 +2.33%
Key statistics
from XBRL data in SEC filingsMarket cap
$305M
Revenue (TTM)
—
Net income (TTM)
-$3.42M
EPS (TTM)
$-0.10
P/E ratio
—
Dividend yield
—
Free cash flow
—
Cash
$6.66M
Total assets
$7.36M
Gross margin
—
52-week range
$1.50 – $15.00
Recent SEC filings
40 most recentAnnual, quarterly & current reports
8-K
Entered a material agreement; Regulation FD disclosure
Jul 16, 2026
10-Q
Quarter ended 2026-03-31
May 15, 2026
8-K
Unregistered sale of equity
May 5, 2026
8-K
Entered a material agreement; Unregistered sale of equity
Apr 24, 2026
8-K
Other events
Apr 9, 2026
10-K
Fiscal year ended 2025-12-31
Mar 31, 2026
10-Q
Quarter ended 2025-09-30
Nov 14, 2025
8-K
Unregistered sale of equity
Oct 30, 2025
8-K
Entered a material agreement; Completed an acquisition or disposition; Unregistered sale of equity; Modified rights of security holders; Change in control; Director or officer change; Amended charter or bylaws; Item 5.05; Item 5.06
Oct 6, 2025
10-Q
Quarter ended 2025-06-30
Aug 7, 2025
10-Q
Quarter ended 2025-03-31
May 15, 2025
10-K
Fiscal year ended 2024-12-31
Mar 28, 2025
10-Q
Quarter ended 2024-09-30
Nov 14, 2024
10-Q
Quarter ended 2024-06-30
Aug 14, 2024
10-Q
Quarter ended 2024-03-31
May 15, 2024
10-K
Fiscal year ended 2023-12-31
Apr 1, 2024
10-Q
Quarter ended 2023-09-30
Nov 14, 2023
Other filings
D
Item 06b
May 1, 2026
4
Apr 20, 2026
4
Apr 20, 2026
424B3
Feb 12, 2026
EFFECT
Feb 9, 2026
CORRESP
Feb 5, 2026
S-1
Jan 23, 2026
UPLOAD
Jan 13, 2026
DRS
Jan 12, 2026
4
Oct 27, 2025
SCHEDULE 13D
Oct 27, 2025
D
Item 06b
Oct 14, 2025
4
Oct 9, 2025
4
Oct 9, 2025
4
Oct 9, 2025
SCHEDULE 13D
Oct 8, 2025
SCHEDULE 13D
Oct 7, 2025
SCHEDULE 13D/A
Oct 6, 2025
SCHEDULE 13D
Oct 6, 2025
4
Oct 2, 2025
SC 14F1
SCHEDULE 14F-1
Aug 29, 2025
3
Nov 30, 2023
3
Nov 30, 2023